1,747 results match your criteria Alloimmunization From Transfusions


Does transfusion of Asian-type DEL red blood cells to D- recipients cause D alloimmunization?

Transfusion 2019 Apr 22. Epub 2019 Apr 22.

Department of Pathology and Laboratory Medicine, MedStar Georgetown University Hospital, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15323DOI Listing

Immunologic risks of whole blood: ABO compatibility, D alloimmunization, and transfusion-related acute lung injury.

Transfusion 2019 Apr;59(S2):1507-1511

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15168DOI Listing
April 2019
1 Read

Red blood cell alloantibodies are associated with increased alloimmunization against human leukocyte antigens.

Transfusion 2019 Apr 13. Epub 2019 Apr 13.

Department of Pathology, Blood Transfusion Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

Background: Alloantibodies recognizing human leukocyte antigens (HLA) can cause immune-mediated refractoriness to platelet transfusion. An association between HLA alloimmunization and red blood cell (RBC) alloimmunization has been suggested but remains uncertain.

Study Design And Methods: We tested for HLA alloantibodies in 660 patients with and without RBC alloantibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15306DOI Listing
April 2019
1 Read

Health literacy and knowledge of chronic transfusion therapy in adolescents with sickle cell disease and caregivers.

Pediatr Blood Cancer 2019 Apr 2:e27733. Epub 2019 Apr 2.

Colorado School of Public Health, Anschutz Medical Campus, University of Colorado, Aurora, Colorado.

Background: Patients with sickle cell disease (SCD) may require chronic transfusion therapy (CTT) for prevention of stroke or other complications. Limited health literacy (HL) is common and is associated with poor health-related knowledge and outcomes in chronic disease. We sought to assess HL and transfusion knowledge in patients with SCD on CTT and their caregivers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27733DOI Listing
April 2019
4 Reads

Performance of middle cerebral artery peak systolic velocity for the prediction of fetal anemia in untransfused and transfused fetuses: a diagnostic test accuracy meta-analysis.

Ultrasound Obstet Gynecol 2019 Apr 1. Epub 2019 Apr 1.

Prenatal Diagnois Unit, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Catalonia, Spain.

Objective: To evaluate the performance of Doppler studies using the middle cerebral artery peak systolic velocity (MCA-PSV) for the prediction of moderate-severe fetal anemia, in untransfused and transfused fetuses.

Methods: A systematic search was performed to identify relevant observational studies evaluating the performance of MCA-PSV using a 1.5 MoM threshold for the prediction of fetal anemia reported in the 2008-2018 period. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/uog.20273
Publisher Site
http://dx.doi.org/10.1002/uog.20273DOI Listing
April 2019
5 Reads

Prevention of delayed hemolytic transfusion reaction.

Authors:
F Pirenne

Transfus Clin Biol 2019 May 22;26(2):99-101. Epub 2019 Feb 22.

Établissement Français du Sang, Inserm U955, Team 2, Paris Est University Creteil (UPEC), France. Electronic address:

Post-transfusion hemolysis is the most frequent immune reaction to transfusion in sickle cell disease. Its frequency is underestimated due to its biological and clinical characteristics. It results principally from the high incidence of alloimmunization in these patients, but no antibodies are detectable in 30% of cases. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S12467820193003
Publisher Site
http://dx.doi.org/10.1016/j.tracli.2019.02.007DOI Listing
May 2019
3 Reads

Transfusion of pathogen-reduced platelet components without leukoreduction.

Transfusion 2019 Mar 28. Epub 2019 Mar 28.

Queen Mary Hospital and University of Hong Kong, Pok Fu Lam, Hong Kong.

Background: Leukoreduction (LR) of platelet concentrate (PC) has evolved as the standard to mitigate risks of alloimmunization, clinical refractoriness, acute transfusion reactions (ATRs), and cytomegalovirus infection, but does not prevent transfusion-associated graft-versus-host disease (TA-GVHD). Amotosalen-ultraviolet A pathogen reduction (A-PR) of PC reduces risk of transfusion-transmitted infection and TA-GVHD. In vitro data indicate that A-PR effectively inactivates WBCs and infectious pathogens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15269DOI Listing
March 2019
3 Reads

Successful Management of the Fetal Severe Anemia Associated with Jra Alloimmunization by Intrauterine Transfusion of Jr(a+) Red Blood Cells.

Case Rep Obstet Gynecol 2019 24;2019:5174989. Epub 2019 Feb 24.

Department of Maternal and Fetal Medicine, Miyagi Children's Hospital, Miyagi 989-3126, Japan.

Objective: We present a case of fetal severe anemia associated with Jra alloimmunization, which was managed using Doppler measurement of the peak systolic velocity of the fetal middle cerebral artery (MCA-PSV) and intrauterine transfusion (IUT) of Jr(a+) red blood cells (RBCs). We also review the previous case reports on fetal or neonatal anemia associated with Jra alloimmunization.

Case Report: A woman with Jra alloimmunization was referred to our department at 29 weeks of gestation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/5174989DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409068PMC
February 2019
1 Read

Intrauterine Transfusion Complicated by Umbilical Artery Thrombosis.

Case Rep Obstet Gynecol 2019 20;2019:5952326. Epub 2019 Feb 20.

Department of Obstetrics, Gynecology and Reproductive Medicine, Division of Maternal-Fetal Medicine, UT Health-School of Medicine at Houston, The Fetal Center, Children's Memorial Hermann Hospital, Houston, TX, USA.

Background: Fetal anemia results from several conditions; however intrauterine transfusion (IUT) remains the treatment for severe cases. The complications of this procedure are rare and yet can result in preterm delivery or fetal death.

Case: 31 y/o G3P2002 with Rh alloimmunization underwent IUT from 19 to 35 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/5952326DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402198PMC
February 2019
2 Reads

Selecting red blood cell units to perform RBCX in patients with sickle cell disease.

Authors:
M Raba

Transfus Apher Sci 2019 Mar 13. Epub 2019 Mar 13.

Delivery and Immunohematology Unit, Etablissement Français du Sang, Centre Hospitalier Lyon Sud, Lyon, France. Electronic address:

Red blood cell exchange (RBCX) is a standard option for treating or preventing complications in patients with sickle cell disease (SCD). According to the patient's blood volume, the amounts of red blood cells (RBC) to be exchanged and the practices of the apheresis and clinical teams, such treatment requires numerous red blood cell units (RBCUs) (3-15 RBCUs per procedure). To perform RBCXs safely and prevent the risk of alloimmunization, appropriate RBCUs must be selected and transfused to replace the sickled RBCs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transci.2019.03.007DOI Listing
March 2019
3 Reads

Neonatal outcomes after percutaneous umbilical cord blood sampling.

J Matern Fetal Neonatal Med 2019 Mar 25:1-6. Epub 2019 Mar 25.

a Department of Obstetrics and Gynecology , Washington University in St Louis School of Medicine , St. Louis , MO , USA.

Objectives: While percutaneous umbilical cord blood sampling (PUBS) and intrauterine transfusion (IUT) are the standards of care for the management of significant fetal anemia, the neonatal complications resultant from these procedures remain poorly understood. Thus, we aimed to compare neonatal outcomes of the patients undergoing percutaneous umbilical cord blood sampling (PUBS) for intrauterine transfusion (IUT) to gestational age- and sex-matched controls with no indication for and not undergoing PUBS.

Methods: This was a retrospective matched cohort study at a single institution from 2000 to 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14767058.2019.1593960DOI Listing
March 2019
1 Read

Phenotype frequencies of Rh (C, c, E, e), M, Mi and Kidd blood group systems among ethnic Thai blood donors from the north-east of Thailand.

Int J Immunogenet 2019 Mar 18. Epub 2019 Mar 18.

Department of Clinical Immunology and Transfusion Sciences, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.

We here report the first study of antigen and phenotype frequencies of Rh (C, c, E, e), M, Mi and Kidd antigens in north-east Thai blood donors. Blood transfusion services aim to ensure availability of adequate and safe blood to minimize the development of transfusion reactions. For pre-transfusion testing, the most important blood group systems are ABO and RhD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iji.12420DOI Listing
March 2019
1 Read

Validated Reference Panel from Renewable Source of Genomic DNA Available for Standardization of Blood Group Genotyping.

J Mol Diagn 2019 Mar 12. Epub 2019 Mar 12.

Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland. Electronic address:

Extended blood group genotyping is an invaluable tool used for prevention of alloimmunization. Genotyping is particularly suitable when antigens are weak, specific antisera are unavailable, or accurate phenotyping is problematic because of a disease state or recent transfusions. In addition, genotyping facilitates establishment of mass-scale patient-matched donor databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2019.02.003DOI Listing
March 2019
3 Reads
4.851 Impact Factor

Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease.

Transfus Clin Biol 2019 May 22;26(2):112-115. Epub 2019 Feb 22.

Department of Laboratory Medicine, 330 Cedar Street, CB 405, New Haven, CT 06520-8035, United States. Electronic address:

Red blood cell (RBC) alloimmunization is more common in patients with sickle cell disease (SCD) than in any other studied patient population. The high prevalence of RBC alloimmunization is multi-factorial, likely involving the chronic hemolysis and inflammatory status of SCD itself, the transfusion burden of patients, and the RH genetic diversity of patients and blood donors, among other reasons. Antibody evanescence, or the decrease of RBC alloantibodies below levels detectable by blood bank testing, occurs frequently with fewer than 30% of alloantibodies estimated to be detected by current screening practices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tracli.2019.02.003DOI Listing
May 2019
2 Reads

Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients.

Transfusion 2019 Mar 8. Epub 2019 Mar 8.

Center for Transfusion and Cellular Therapy, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia.

Background: Delayed hemolytic transfusion reactions (DHTRs) are serious complications of RBC transfusion that can occur in previously alloimmunized patients. Patients who require episodic transfusions during heightened inflammatory states, such as patients with sickle cell disease (SCD), are particularly prone to alloimmunization and developing DHTRs with hyperhemolysis. While efforts to mitigate these hemolytic episodes via immunosuppressive drugs can be employed, the relative efficacy of various treatment options remains incompletely understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15227DOI Listing
March 2019
3 Reads

Adverse transfusion reactions in patients with aplastic anaemia or myelodysplastic syndromes.

Vox Sang 2019 Feb 28. Epub 2019 Feb 28.

Department of Vigilance, Haemovigilance, Site de Lyon Décines, Etablissement français du Sang Auvergne Rhône-Alpes, Décines-Charpieu Cedex, France.

Background And Objectives: Patients with aplastic anaemia or myelodysplastic syndromes frequently receive transfusions in an attempt to correct anaemia and/or thrombocytopenia, putting them at risk of adverse transfusion reactions. The aim of this study is to evaluate the incidence and the types of adverse transfusion reactions in these patients.

Materials And Methods: Adverse transfusion reaction reported in transfused patients with aplastic anaemia or myelodysplastic syndromes from all the hospitals in the Auvergne-Rhône-Alpes region of France were extracted from the national haemovigilance database system and analysed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/vox.12765DOI Listing
February 2019
8 Reads

Transfusion-related red blood cell alloantibodies: induction and consequences.

Blood 2019 Feb 26. Epub 2019 Feb 26.

Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, United States

Blood transfusion is the most common procedure completed during a given hospitalization in the United States. Although often life-saving, transfusions are not risk-free. One sequelae that occurs in a subset of red blood cell (RBC) transfusion recipients is the development of alloantibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-08-833962DOI Listing
February 2019
1 Read

Methods for blood group antigens detection: cost-effectiveness analysis of phenotyping and genotyping.

Hematol Transfus Cell Ther 2019 Jan-Mar;41(1):44-49. Epub 2018 Oct 30.

Universidade Estadual de Maringá (UEM), Maringá, PR, Brazil.

Background: Alloimmunization is a major problem in transfusion practice due to the clinical complications of the patients and the difficulty of choosing a unit of compatible blood product. Serological methods are widely used in blood banks, but they not always determine the phenotype. Thus, genotyping is an important complement to the serology tool as it allows one to predict the phenotype from deoxyribonucleic acid (DNA) with high accuracy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.htct.2018.06.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371408PMC
October 2018

First report of the rare RhCE-depleted D--phenotype in sixteen people of Iranian origin.

Vox Sang 2019 Apr 19;114(3):256-261. Epub 2019 Feb 19.

Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Background And Objectives: In transfusion medicine, it may be a challenge to acquire compatible blood for patients who have clinically important alloantibodies to high-prevalence antigens. The aim of this study was to study prevalence of rare D-- phenotype in samples from patients and their relatives referred to the Immunohematology reference laboratory of the Iranian Blood Transfusion Organization and the detection and identification of the phenotype and associated antibodies, particularly in an antenatal setting. This is the first report of the cases evaluated by the IBTO and family studies of the D-- proposita in Iran and possibly the first attempted comprehensive study in the current transfusion-related literatures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/vox.12738DOI Listing
April 2019
2 Reads

Molecular genotyping of clinically important blood group antigens in patients with thalassaemia.

Indian J Med Res 2018 Dec;148(6):713-720

Department of Transfusion Medicine, ICMR-National Institute of Immunohaematology, KEM Hospital Campus, Mumbai, India.

Background & Objectives: In multitransfused thalassaemic patients, haemagglutination fails to phenotype the patient's blood group antigens due to the presence of donor-derived erythrocytes. DNA-based methods can overcome the limitations of haemagglutination and can be used to determine the correct antigen profile of these patients. This will facilitate the procurement of antigen-matched blood for transfusion to multitransfused patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijmr.IJMR_455_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396563PMC
December 2018
2 Reads

Overcoming challenges of venous thromboembolism in sickle cell disease treatment.

Expert Rev Hematol 2019 Mar 8;12(3):173-182. Epub 2019 Mar 8.

a Department of Hematology , Johns Hopkins School of Medicine , Baltimore , MD , USA.

Introduction: Venous thromboembolism (VTE) is a common comorbid condition found in sickle cell disease (SCD) and is associated with increased mortality for adults with SCD. The pathophysiology that leads to the thrombophilic state in SCD has been previously reviewed; however, evidence-based guidelines to aid in diagnosis, prevention, and management of VTE are lacking. Areas covered: This review article will cover the pathophysiology underlying the hypercoagulable state, the epidemiology of VTE, and management strategies of VTE in SCD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583554DOI Listing
March 2019
1 Read

Anti-N and anti-Do immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature.

Transfusion 2019 Feb 15. Epub 2019 Feb 15.

Division of Hematology and Oncology, University of Florida, Gainesville, Florida.

Background: Delayed hemolytic transfusion reaction (DHTR) with hyperhemolysis is a potentially fatal complication resulting from alloimmunization that can cause severe hemolysis of both transfused and intrinsic red blood cells (RBCs). Patients with sickle cell disease often receive multiple RBC units during their lifetime and thus are likely to develop alloantibodies that increase the risk for DHTR. Treatment to decrease hemolysis includes intravenous immunoglobulin (IVIG), steroids, eculizumab, rituximab, and plasmapheresis in addition to erythropoietin (EPO), intravenous (IV) iron, vitamin B12, and folate to support erythropoiesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15198DOI Listing
February 2019
5 Reads

Red blood cell alloimmunization in multi-transfused patients with chronic kidney disease in Port Harcourt, South-South Nigeria.

Afr Health Sci 2018 Dec;18(4):979-987

Department of Internal Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria.

Background: Serological safety is an integral part of overall safety for blood banks.

Objectives: The aim of the study was to determine the prevalence and specificities of red blood cell alloimmunization in multi-transfused patients with chronic kidney disease (CKD).

Methods: A cross-sectional case-control study carried out at the University of Port Harcourt Teaching Hospital in which 186 patients with CKD were enrolled consecutively, 124 had received multiple transfusions (more than one unit of blood in one month, or at least 10 units within 3 months), while 62 had never been transfused. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4314/ahs.v18i4.18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354886PMC
December 2018
2 Reads

Red blood cell alloimmunization and minor red blood cell antigen phenotypes in transfused Ghanaian patients with sickle cell disease.

Transfusion 2019 Feb 13. Epub 2019 Feb 13.

Department of Experimental Immunohematology, Sanquin, Amsterdam, Netherlands.

Background: The routine pretransfusion investigations in Southern Ghana involve only ABO-D blood group typing and ABO compatibility testing without screening for irregular red blood cell (RBC) antibodies. The prevalence and specificities of RBC antibodies and frequencies of most minor blood group antigens in transfused patients with sickle cell disease (SCD) in Ghana are not known and are the objectives of this study.

Study Design And Methods: This was a cross-sectional study that investigated transfused patients with SCD for the presence of irregular RBC antibodies and Rhesus, Kell, Duffy, Kidd, and Ss antigens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15197DOI Listing
February 2019
7 Reads
3.225 Impact Factor

Allogeneic major histocompatibility complex antigens are necessary and sufficient for partial tolerance induced by transfusion of pathogen reduced platelets in mice.

Vox Sang 2019 Apr 7;114(3):207-215. Epub 2019 Feb 7.

Vitalant Research Institute, San Francisco, CA, USA.

Background And Objectives: Alloimmunization is common following transfusion with platelet-rich plasma (PRP) and can cause complications such as platelet refractoriness or transplant rejection. It has previously been shown that pathogen reduction of PRP with riboflavin and UV light (UV+R) can protect against alloimmunization in mice and induce partial tolerance to subsequent transfusions.

Materials And Methods: Using B6 H2 congenic mice, this study evaluated the relative contributions of major histocompatibility complex (MHC) antigens and minor antigens to both the alloresponse to PRP transfusion and the partial tolerance induced by UV+R treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/vox.12756DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465144PMC
April 2019
6 Reads

[Delayed hemolytic reaction to transfusion in sickle cell anemia. Report of one case].

Rev Med Chil 2018 Nov;146(11):1347-1350

Servicio de Medicina, Santiago, Chile.

Sickle cell anemia was a rare disease in Chile, especially in adults, however the recent immigration wave from Haiti is changing this scenario. We report a 29 year old black female from Haiti with a non-disclosed history of sickle cell anemia. She was transfused with two units of red blood cells, found unconscious and with jaundice five days later and admitted to the hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4067/S0034-98872018001101347DOI Listing
November 2018
7 Reads

How clinically important are non-D Rh antibodies?

Acta Obstet Gynecol Scand 2019 Feb 5. Epub 2019 Feb 5.

Department of Obstetrics and Gynaecology, The University of Melbourne, The Royal Women's Hospital, Parkville, Victoria, Australia.

Introduction: The advent of RhD immunoglobulin prophylaxis to prevent maternal RhD alloimmunization has reduced the incidence of this condition and its associated poor outcomes. Consequently, non-D Rh antibodies now account for a greater proportion of alloimmunized pregnancies. These antibodies have been the subject of comparatively little research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/aogs.13555DOI Listing
February 2019
3 Reads

Fetal anemia: Diagnosis and management.

Best Pract Res Clin Obstet Gynaecol 2019 Jan 9. Epub 2019 Jan 9.

Department of Obstetrics and Gynaecology, University of Brescia, Brescia, Italy.

Fetal anemia has been known for many years as a dangerous complication of pregnancy. Its most common causes are maternal alloimmunization and parvovirus B19 infection, although it can be associated with many different pathological conditions including fetal aneuploidies, vascular tumors, and arteriovenous malformations of the fetus or placenta and inherited conditions such as alpha-thalassemia or genetic metabolic disorders. Doppler ultrasonographic assessment of the peak velocity of systolic blood flow in the middle cerebral artery for the diagnosis of fetal anemia and intravascular intrauterine transfusion for its treatment are the current practice standards. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpobgyn.2019.01.001DOI Listing
January 2019
4 Reads

Genetically-engineered pigs as sources for clinical red blood cell transfusion: What pathobiological barriers need to be overcome?

Blood Rev 2019 05 28;35:7-17. Epub 2019 Jan 28.

Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address:

An alternative to human red blood cells (RBCs) for clinical transfusion would be advantageous, particularly in situations of massive acute blood loss (where availability and compatibility are limited) or chronic hematologic diseases requiring frequent transfusions (resulting in alloimmunization). Ideally, any alternative must be neither immunogenic nor pathogenic, but readily available, inexpensive, and physiologically effective. Pig RBCs (pRBCs) provide a promising alternative due to their several similarities with human RBCs, and our increasing ability to genetically-modify pigs to reduce cellular immunogenicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2019.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467751PMC
May 2019
5 Reads

Development of a recombinant anti-Vel immunoglobulin M to identify Vel-negative donors.

Transfusion 2019 Apr 31;59(4):1359-1366. Epub 2019 Jan 31.

Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, AUMC, Amsterdam, The Netherlands.

Background: Alloimmunization against the high-frequency Vel blood group antigen may result in transfusion reactions or hemolytic disease of fetus and newborn. Patients with anti-Vel alloantibodies require Vel-negative blood but Vel-negative individuals are rare (1:4000). Identification of Vel-negative donors ensures availability of Vel-negative blood; however, accurate Vel blood group typing is difficult due to variable Vel antigen expression and limited availability of anti-Vel typing sera. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15147DOI Listing
April 2019
15 Reads

Alloimmunogenicity of an isolated MHC allele is affected by the context of MHC mismatch in a murine model.

Transfusion 2019 Feb 25;59(2):744-753. Epub 2019 Jan 25.

BloodworksNW Research Institute, Seattle, Washington.

Background: Humoral alloimmunization to human leukocyte antigen (HLA) can represent a barrier to solid-organ transplantation, can lead to a refractory state in patients requiring platelet transfusion, and can also contribute to transfusion-related acute lung injury (TRALI). While exposure to HLA-mismatched cells/tissues are generally required for HLA alloimmunization, the effect of the extent of major histocompatibility complex (MHC) mismatch between donor and recipient is poorly understood.

Study Design And Methods: A novel mouse was generated that allows the expression of a single MHC Class I alloantigen, K . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15109DOI Listing
February 2019
4 Reads

More efficient exchange of sickle red blood cells can be achieved by exchanging the densest red blood cells: An ex vivo proof of concept study.

Transfus Apher Sci 2019 Feb 2;58(1):100-106. Epub 2019 Jan 2.

Division of Transfusion Medicine and Therapeutic Pathology, Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, United States.

Background: In sickle cell disease (SCD), red blood cells (RBCs) containing hemoglobin S can be denser than RBCs containing wild-type hemoglobin, especially when dehydrated. We hypothesize that targeting denser RBCs during red blood cell (RBC) exchange for SCD could result in more efficient removal of dehydrated, sickled RBCs and preservation of non-sickled RBCs.

Study Design And Methods: Waste products from RBC exchanges for SCD were used as "simulated patients". Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14730502183040
Publisher Site
http://dx.doi.org/10.1016/j.transci.2018.12.005DOI Listing
February 2019
13 Reads

Predisposing factors for anti-D immune response in D patients with chronic liver disease transfused with D platelet concentrates.

Transfusion 2019 Apr 3;59(4):1353-1358. Epub 2019 Jan 3.

Etablissement Français du Sang Ile de France, Hôpital Henri Mondor, Créteil, France.

Background: Recent reports have indicated that the risk of anti-D alloimmunization following D-incompatible platelet (PLT) transfusion is low in hematology and oncology patients. We investigated the rate of anti-D alloimmunization in RhD-negative (D ) patients with chronic liver disease transfused with D platelet concentrates (PCs) and the factors involved, at a liver transplant (LT) center.

Study Design And Methods: We reviewed the blood bank database from January 2003 to October 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15129DOI Listing
April 2019
17 Reads

Clinical outcome of transfusions with extended red blood cell matching in β-thalassemia patients: A single-center experience.

Transfus Apher Sci 2019 Feb 5;58(1):65-71. Epub 2018 Dec 5.

U.O.C. Division of Immunohematology, Transfusion Medicine and Transplant Immunology, Department of Internal Medicine and Specialistics, Azienda Ospedaliera Universitaria (AOU), University of Campania "L. Vanvitelli", Naples, Italy; Department of Medical, Surgical, Neurological, Metabolic and Geriatric Sciences, University of Campania "L. Vanvitelli", Naples, Italy.

Background: The development of alloantibodies may complicate the management of patients with β-thalassemia. An extended antigenic matching may reduce the risk of alloimmunization. Our previous study showed that the introduction of molecular red blood cell (RBC) typing allows finding suitable blood units for multi-transfused patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transci.2018.11.006DOI Listing
February 2019
4 Reads

A locus on chromosome 5 shows African ancestry-limited association with alloimmunization in sickle cell disease.

Blood Adv 2018 Dec;2(24):3637-3647

Department of Molecular and Human Genetics and.

Red blood cell (RBC) transfusion remains a critical therapeutic intervention in sickle cell disease (SCD); however, the apparent propensity of some patients to regularly develop RBC alloantibodies after transfusion presents a significant challenge to finding compatible blood for so-called alloimmunization responders. Predisposing genetic loci have long been thought to contribute to the responder phenomenon, but to date, no definitive loci have been identified. We undertook a genome-wide association study of alloimmunization responder status in 267 SCD multiple transfusion recipients, using genetic estimates of ancestral admixture to bolster our findings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018020594DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306880PMC
December 2018
3 Reads

Efficacy of Antenatal Intravenous Immunoglobulin Treatment in Pregnancies at High Risk due to Alloimmunization to Red Blood Cells.

Transfus Med Hemother 2018 Nov 31;45(6):429-436. Epub 2018 Oct 31.

Department of Gynecology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany.

Background: Alloimmunization to red blood cells (RBCs) may result in fetal anemia prior to 20 weeks gestation. The question as to whether early commencement of antenatal treatment with high-dose intravenous immunoglobulins (IVIG) may prevent or at least delay the development of fetal anemia in the presence of alloantibodies to RBCs is highly relevant.

Patients And Results: Here we describe a patient with high-titer anti-K and two other severely affected pregnant women with a history of recurrent pregnancy loss due to high-titer anti-D or anti-D plus anti-C. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000490154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288630PMC
November 2018
3 Reads

Human Platelet Antigens in Brazilian Multiethnic Populations: Occurrence of Regional Variation and Frequency in a Large Urban Center (Belo Horizonte).

Transfus Med Hemother 2018 Nov 11;45(6):388-396. Epub 2018 May 11.

Serviço de Pesquisa, Fundação Centro de Hematologia e Hemoterapia de Minas Gerais, Fundação Hemominas, Belo Horizonte, Brazil.

Background: The frequency of human platelet antigens (HPA) varies according to ethnicity, which causes differences in the morbidity of alloimmune and autoimmune thrombocytopenic disorders in different populations. Studies on HPA frequencies in Brazil have reported differences among Brazilian populations produced by the diverse degrees of admixture throughout the country.

Methods: In the present study, we investigated the variation of HPA distribution in Brazil, compared with worldwide populations, and describe the frequencies of HPA-1, -2, -3, -5, and -15 in a large urban center in Southern Brazil (Belo Horizonte) based on a sample of blood donors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000488469DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288627PMC
November 2018
19 Reads

Marginal Zone B Cells Induce Alloantibody Formation Following RBC Transfusion.

Front Immunol 2018 16;9:2516. Epub 2018 Nov 16.

Department of Laboratory Medicine and Pathology, Center for Transfusion Medicine and Cellular Therapies, Emory University School of Medicine, Atlanta, GA, United States.

Red blood cell (RBC) alloimmunization represents a significant immunological challenge for some patients. While a variety of immune constituents likely contribute to the initiation and orchestration of alloantibodies to RBC antigens, identification of key immune factors that initiate alloantibody formation may aid in the development of a therapeutic modality to minimize or prevent this process. To define the immune factors that may be important in driving alloimmunization to an RBC antigen, we determined the specific immune compartment and distinct cells that may initially engage transfused RBCs and facilitate subsequent alloimmunization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.02516DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250814PMC
November 2018
16 Reads

Shifting ground and gaps in transfusion support of patients with hematological malignancies.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):553-560

Laboratory Medicine and Pathobiology (Transfusion Medicine) and Medicine (Clinical Hematology), University Health Network/University of Toronto, Toronto, ON, Canada.

The transfusion support of hematological malignancies considers 2 dimensions: the quantity of what we order (in terms of triggers, doses, targets, and intervals), and the special qualities thereof (with respect to depths of matching and appropriate product modifications). Meanwhile, transfusion-related enhancements in the quantity and quality of life may not be dose dependent but rather tempered by unintended patient harms and system strains from overexposure. Evidence and guidelines concur in endorsing clinically noninferior conservative red blood cell (RBC) transfusion care strategies (eg, triggering at hemoglobin <7-8 g/dL and in single-unit doses for stable, nonbleeding inpatients). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.553DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246005PMC
November 2018
5 Reads

Red Blood Cell Alloimmunization in Multitransfused Pediatric Population in a Tertiary Care Hospital.

Indian J Pediatr 2019 Mar 4;86(3):245-249. Epub 2018 Dec 4.

Department of Pediatrics, Government Medical College, Thiruvananthapuram, Kerala, India.

Objectives: To estimate the prevalence and specificity pattern of red blood cell (RBC) alloimmunization among pediatric multitransfused patients, and to identify the factors associated with alloimmunization.

Methods: This was a descriptive cross-sectional study conducted among mutitransfused pediatric patients over a period of two years. The relevant clinical details of patients were collected, and RBC antibody screening was done. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12098-018-2815-9DOI Listing
March 2019
5 Reads

The role of pathogen-reduced platelet transfusions on HLA alloimmunization in hemato-oncological patients.

Transfusion 2019 Feb 30;59(2):470-481. Epub 2018 Nov 30.

Center for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands.

Background: Platelet transfusions can induce alloimmunization against HLA antigens. The use of pathogen-reduced platelet concentrates (PCs) was suggested to reduce HLA alloimmunization and concomitant transfusion refractoriness.

Methods: This study investigated HLA alloimmunization in available samples from 448 hemato-oncological patients who were randomized for the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial to receive either untreated or pathogen-reduced PCs (Mirasol, Terumo BCT Inc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15056DOI Listing
February 2019
4 Reads

Multiplex blood group typing by cellular surface plasmon resonance imaging.

Transfusion 2019 Feb 29;59(2):754-761. Epub 2018 Nov 29.

Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Background: Blood-group typing of donors and patients is essential to avoid incompatible transfusions. Transfusion of incompatible RBCs may result in alloimmunization complicating future transfusions or in the presence of antibodies in adverse reactions. With more than 300 blood group antigens identified, it is difficult to provide fully compatible blood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15071DOI Listing
February 2019
8 Reads

Prevalence and clinical significances of red cell alloimmunization and red cell bound immunoglobulin G in polytransfused patients with thalassemias.

Hematology 2019 Dec;24(1):208-214

a Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital , Mahidol University , Bangkok , Thailand.

The study was to determine the prevalence and clinical significances of red blood cell (RBC)-bound IgG as detected by flow cytometry in polytransfused patients with thalassemias. Relationship of the presence of RBC-bound IgG with RBC alloimmunization was also evaluated. This study included 59 polytransfused patients with β-thalassemia disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2018.1549818DOI Listing
December 2019
5 Reads

The prevalence, alloimmunization risk factors, antigenic exposure, and evaluation of antigen-matched red blood cells for thalassemia transfusions: a 10-year experience at a tertiary care hospital.

Transfusion 2019 01 15;59(1):177-184. Epub 2018 Nov 15.

Blood Transfusion Center, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

Background: Hemoglobin E-β thalassemia and homozygous β -thalassemia are the most common chronic transfusion-dependent thalassemias in Thailand. Patients with these conditions can experience clinical complications such as RBC alloimmunization. In this study we aimed to determine the prevalence, alloimmunization risk factors, antigenic exposure, and evaluation of antigen- (C, c, E, e, Mi ) matched RBC transfusion. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/trf.15002
Publisher Site
http://dx.doi.org/10.1111/trf.15002DOI Listing
January 2019
19 Reads

Red Blood Cell Alloimmunization in Korean Patients With Myelodysplastic Syndrome and Liver Cirrhosis.

Ann Lab Med 2019 Mar;39(2):218-222

Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Red blood cell (RBC) alloimmunization varies across human populations and ethnic groups. We evaluated the characteristics of RBC alloimmunization and compared the risk of alloimmunization in Korean patients with myelodysplastic syndrome (MDS) and liver cirrhosis (LC), two representative diseases in which chronic transfusion is required. In total, 115 MDS patients and 202 LC patients transfused with RBCs between 2013 and 2015 were retrospectively included. Read More

View Article

Download full-text PDF

Source
https://synapse.koreamed.org/DOIx.php?id=10.3343/alm.2019.39
Publisher Site
http://dx.doi.org/10.3343/alm.2019.39.2.218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240531PMC
March 2019
14 Reads

Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses.

JCI Insight 2018 11 15;3(22). Epub 2018 Nov 15.

Center for Transfusion Medicine and Cellular Therapies, Department of Laboratory Medicine and Pathology.

RBC alloimmunization represents a significant immunological challenge for patients requiring lifelong transfusion support. The majority of clinically relevant non-ABO(H) blood group antigens have been thought to drive antibody formation through T cell-dependent immune pathways. Thus, we initially sought to define the role of CD4+ T cells in formation of alloantibodies to KEL, one of the leading causes of hemolytic transfusion reactions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.121631DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302935PMC
November 2018
9 Reads

Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III).

Transfusion 2019 01 14;59(1):217-225. Epub 2018 Nov 14.

Department of Laboratory Medicine, Yale University, New Haven, Connecticut.

Background: Little information exists on red blood cell (RBC) alloimmunization in healthy US blood donors, despite the potential significance for donors themselves, blood recipients, and the blood center.

Study Design And Methods: Donor/donation data were sourced from the Recipient Epidemiology and Donor Evaluation Study-III, which contains information from four US blood centers during 2012 through 2016. Multivariable logistic regression was used to assess prevalence of positive antibody screen by donor demographics, blood type, parity, and transfusion history. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/trf.15004
Publisher Site
http://dx.doi.org/10.1111/trf.15004DOI Listing
January 2019
23 Reads

Mild Allergic Transfusion Reactions: Impact of Associated Clinical Symptoms?

Am J Clin Pathol 2019 Feb;151(3):344-348

Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.

Objectives: Transfusions are often needlessly aborted after occurrence of a mild allergic transfusion reaction (ATR), leading to wastage and reexposure of recipients to additional blood products (with potential alloimmunization). We aimed to determine the symptoms associated with such reactions (along with other parameters) as a possible reason of concern for transfusionists aborting such transfusions.

Methods: We reviewed the symptomology of all mild ATRs (as well as the associated wastage and costs of aborted transfusions) at an academic medical center that occurred over a period of 1 year. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ajcp/advance-article/doi/10.1093/aj
Publisher Site
http://dx.doi.org/10.1093/ajcp/aqy150DOI Listing
February 2019
14 Reads

Maternal HLA-G*01:01:01:04 protects from anti-HLA-class II immunization in pregnant women.

Hum Immunol 2019 Feb 7;80(2):120-125. Epub 2018 Nov 7.

Aix Marseille Univ, CNRS, EFS, ADES, "Biologie des Groupes Sanguins", Marseille, France; Etablissement Français du Sang PACA Corse, Marseille, France. Electronic address:

Factors determining anti-HLA immunization are poorly understood, although anti-HLA immunization following pregnancy is well described. The HLA-G molecule has been extensively described for its implication in immunological tolerance, especially during pregnancy. Transplant studies show an association between HLA-G haplotypes and alloimmunization. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01988859183019
Publisher Site
http://dx.doi.org/10.1016/j.humimm.2018.11.003DOI Listing
February 2019
17 Reads